Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in...

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Single-target cancer therapies often exhibit limited efficacy due to tumor heterogeneity and pathway redundancy.
• Developing multi-targeted therapeutics is crucial for overcoming resistance and improving patient outcomes in cancer treatment.

Purpose of the Study:

• To characterize a novel bifunctional molecule, ENb-TRAIL, targeting both epidermal growth factor receptor (EGFR) and death receptors (DR).
• To investigate the therapeutic efficacy and underlying mechanisms of ENb-TRAIL in various cancer types, particularly those resistant to monotherapies.
• To evaluate the in vivo efficacy of ENb-TRAIL in a glioblastoma model.

Main Methods:

• Characterization of the bifunctional ENb-TRAIL molecule.
• In vitro studies using pharmacological inhibition, genetic loss of function, and Förster Resonance Energy Transfer (FRET).
• In vivo studies using an orthotopic glioblastoma resection model with engineered stem cells (SC) encapsulated in synthetic extracellular matrix (sECM).

Main Results:

• ENb-TRAIL demonstrated therapeutic efficacy in cancer cells resistant to EGFR antagonist or DR agonist monotherapies.
• ENb-TRAIL blocks EGFR signaling, induces DR5 clustering, and primes cells for caspase-mediated apoptosis.
• In vivo treatment with sECM-encapsulated SC-ENb-TRAIL significantly reduced tumor burden and increased survival in a glioblastoma model.

Conclusions:

• ENb-TRAIL offers a novel dual-targeting strategy for cancer therapy by simultaneously inhibiting proliferation and inducing apoptosis.
• This approach provides new mechanistic insights into targeting multiple receptor signaling pathways.
• ENb-TRAIL presents a promising candidate for clinical translation in treating diverse cancer types.